within Pharmacolibrary.Drugs.ATC.J;

model J04AM07
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.00023333333333333333,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.015000000000000001,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04AM07</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A fixed-dose combination antibacterial therapy containing rifampicin, ethambutol, and isoniazid, primarily used for the treatment of tuberculosis (TB). This combination is approved and recommended by WHO for TB therapy to improve adherence and reduce development of drug resistance.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated from the literature on the individual drugs in adult TB patients, as no published pharmacokinetic model was found for the fixed-dose combination of all three drugs together.</p><h4>References</h4><ol><li><p>Sibley, L, et al., &amp; Sharpe, S (2022). Determination of the Pharmacokinetics and Pharmacodynamics of Isoniazid, Rifampicin, Pyrazinamide and Ethambutol in a Cross-Over Cynomolgus Macaque Model of . <i>Pharmaceutics</i> 14(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics14122666\">10.3390/pharmaceutics14122666</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36559163/\">https://pubmed.ncbi.nlm.nih.gov/36559163</a></p></li><li><p>Xu, J, et al., &amp; Lu, Y (2013). Oral bioavailability of rifampicin, isoniazid, ethambutol, and pyrazinamide in a 4-drug fixed-dose combination compared with the separate formulations in healthy Chinese male volunteers. <i>Clinical therapeutics</i> 35(2) 161–168. DOI:<a href=\"https://doi.org/10.1016/j.clinthera.2013.01.003\">10.1016/j.clinthera.2013.01.003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23410999/\">https://pubmed.ncbi.nlm.nih.gov/23410999</a></p></li><li><p>Chen, C, et al., &amp; Simonsson, US (2016). Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse. <i>European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences</i> 93 319–333. DOI:<a href=\"https://doi.org/10.1016/j.ejps.2016.07.017\">10.1016/j.ejps.2016.07.017</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27473307/\">https://pubmed.ncbi.nlm.nih.gov/27473307</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04AM07;
